{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:54:10Z","timestamp":1783180450103,"version":"3.54.6"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["JP 23K08221"],"award-info":[{"award-number":["JP 23K08221"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10388-025-01146-3","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:58:49Z","timestamp":1752141529000},"page":"631-640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["DCF-resistant ESCC redevelops drug sensitivity when combined with calcium channel blockers due to ER stress response"],"prefix":"10.1007","volume":"22","author":[{"given":"Wenjie","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-2755","authenticated-orcid":false,"given":"Satoru","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Takimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kawakubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Saya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"1146_CR1","unstructured":"World Health Organization. Globocan factsheets of Esophageal. World Health Organization: Internation Agency for research on cancer; 2022. p. 2."},{"key":"1146_CR2","unstructured":"Foundation for Promotion of Cancer Research. Cancer statistics in Japan 2022; 2022."},{"issue":"4","key":"1146_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s10388-024-01062-y","volume":"21","author":"Y Sato","year":"2024","unstructured":"Sato Y, et al. Response to chemotherapy could predict the prognosis of esophageal squamous cell carcinoma treated with neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) followed by surgery: long-term results in a single institute. Esophagus. 2024;21(4):514\u201322.","journal-title":"Esophagus"},{"issue":"1","key":"1146_CR4","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1097\/SLA.0000000000005533","volume":"278","author":"S Matsuda","year":"2023","unstructured":"Matsuda S, et al. Real-world evaluation of the efficacy of neoadjuvant DCF over CF in esophageal squamous cell carcinoma: propensity score-matched analysis from 85 authorized Institutes for Esophageal Cancer in Japan. Ann Surg. 2023;278(1):e35\u201342.","journal-title":"Ann Surg"},{"issue":"10447","key":"1146_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet. 2024;404(10447):55\u201366.","journal-title":"Lancet"},{"issue":"3","key":"1146_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10388-023-00994-1","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, et al. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2. Esophagus. 2023;20(3):373\u201389.","journal-title":"Esophagus"},{"issue":"2","key":"1146_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dote.12479","volume":"30","author":"Y Miyawaki","year":"2017","unstructured":"Miyawaki Y, et al. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. Dis Esophagus. 2017;30(2):1\u20138.","journal-title":"Dis Esophagus"},{"issue":"1","key":"1146_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41392-023-01518-0","volume":"8","author":"Y Yang","year":"2023","unstructured":"Yang Y, et al. Comprehensive landscape of resistance mechanisms for neoadjuvant therapy in esophageal squamous cell carcinoma by single-cell transcriptomics. Signal Transduct Target Ther. 2023;8(1):298.","journal-title":"Signal Transduct Target Ther"},{"issue":"73","key":"1146_CR9","doi-asserted-by":"publisher","first-page":"33832","DOI":"10.18632\/oncotarget.26112","volume":"9","author":"S Okazaki","year":"2018","unstructured":"Okazaki S, et al. Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells. Oncotarget. 2018;9(73):33832\u201343.","journal-title":"Oncotarget"},{"issue":"2","key":"1146_CR10","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.3892\/mmr.2015.3768","volume":"12","author":"SV Govindan","year":"2015","unstructured":"Govindan SV, et al. Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines. Mol Med Rep. 2015;12(2):3025\u201332.","journal-title":"Mol Med Rep"},{"issue":"12","key":"1146_CR11","doi-asserted-by":"publisher","first-page":"6443","DOI":"10.21873\/anticanres.13858","volume":"39","author":"MVS Amaral","year":"2019","unstructured":"Amaral MVS, et al. Establishment of drug-resistant cell lines as a model in experimental oncology: a review. Anticancer Res. 2019;39(12):6443\u201355.","journal-title":"Anticancer Res"},{"key":"1146_CR12","unstructured":"Dobin A. STAR manual 2.7.10a, O.S. University, Editor; 2022. p. 62."},{"issue":"22","key":"1146_CR13","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1111\/febs.17272","volume":"291","author":"W Bai","year":"2024","unstructured":"Bai W, et al. EGF\/EGFR-YAP1\/TEAD2 signaling upregulates STIM1 in vemurafenib resistant melanoma cells. FEBS J. 2024;291(22):4969\u201383.","journal-title":"FEBS J"},{"key":"1146_CR14","doi-asserted-by":"publisher","first-page":"956154","DOI":"10.3389\/fphar.2022.956154","volume":"13","author":"D Correia da Silva","year":"2022","unstructured":"Correia da Silva D, et al. A pipeline for natural small molecule inhibitors of endoplasmic reticulum stress. Front Pharmacol. 2022;13:956154.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1146_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.72","volume":"6","author":"T Avril","year":"2017","unstructured":"Avril T, Vauleon E, Chevet E. Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers. Oncogenesis. 2017;6(8): e373.","journal-title":"Oncogenesis"},{"issue":"27","key":"1146_CR16","doi-asserted-by":"publisher","first-page":"20993","DOI":"10.1074\/jbc.M110.126599","volume":"285","author":"JD Blais","year":"2010","unstructured":"Blais JD, et al. A small molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1) with selectively reversible thiol reactivity. J Biol Chem. 2010;285(27):20993\u20131003.","journal-title":"J Biol Chem"},{"issue":"3","key":"1146_CR17","doi-asserted-by":"publisher","first-page":"101042831769597","DOI":"10.1177\/1010428317695970","volume":"39","author":"Y Wang","year":"2017","unstructured":"Wang Y, et al. Intracellular calcium promotes radioresistance of non-small cell lung cancer A549 cells through activating Akt signaling. Tumour Biol. 2017;39(3):1010428317695970.","journal-title":"Tumour Biol"},{"issue":"7586","key":"1146_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nature17041","volume":"529","author":"M Wang","year":"2016","unstructured":"Wang M, Kaufman RJ. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature. 2016;529(7586):326\u201335.","journal-title":"Nature"},{"issue":"1","key":"1146_CR19","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1186\/s12967-024-05920-2","volume":"22","author":"CR Yu","year":"2024","unstructured":"Yu CR, et al. Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum\/Golgi stress and apoptosis. J Transl Med. 2024;22(1):1095.","journal-title":"J Transl Med"},{"issue":"4","key":"1146_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3390\/cells11040632","volume":"11","author":"J Khaled","year":"2022","unstructured":"Khaled J, et al. Drug resistance and endoplasmic reticulum stress in hepatocellular carcinoma. Cells. 2022;11(4):632.","journal-title":"Cells"},{"issue":"5","key":"1146_CR21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2008.10.011","volume":"135","author":"PI Merksamer","year":"2008","unstructured":"Merksamer PI, Trusina A, Papa FR. Real-time redox measurements during endoplasmic reticulum stress reveal interlinked protein folding functions. Cell. 2008;135(5):933\u201347.","journal-title":"Cell"},{"key":"1146_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-pathol-012513-104649","volume":"10","author":"SA Oakes","year":"2015","unstructured":"Oakes SA, Papa FR. The role of endoplasmic reticulum stress in human pathology. Annu Rev Pathol. 2015;10:173\u201394.","journal-title":"Annu Rev Pathol"},{"issue":"6059","key":"1146_CR23","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1126\/science.1209038","volume":"334","author":"P Walter","year":"2011","unstructured":"Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334(6059):1081\u20136.","journal-title":"Science"},{"issue":"1","key":"1146_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12943-017-0657-0","volume":"16","author":"IC Salaroglio","year":"2017","unstructured":"Salaroglio IC, et al. PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy. Mol Cancer. 2017;16(1):91.","journal-title":"Mol Cancer"},{"issue":"22","key":"1146_CR25","doi-asserted-by":"publisher","first-page":"20156","DOI":"10.1021\/acs.jmedchem.4c01467","volume":"67","author":"M Lv","year":"2024","unstructured":"Lv M, et al. Ruthenium(ii)-arene complex triggers immunogenic ferroptosis for reversing drug resistance. J Med Chem. 2024;67(22):20156\u201371.","journal-title":"J Med Chem"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-025-01146-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-025-01146-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-025-01146-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T09:02:41Z","timestamp":1758531761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-025-01146-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1146"],"URL":"https:\/\/doi.org\/10.1007\/s10388-025-01146-3","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yuko Kitagawa received research fund from TAIHO Pharmaceutical Co., LTD., CHUGAI Pharmaceutical Co., LTD., Kyouwa Kirin Co., LTD., Nippon Kayaku Co., LTD., DAIICHI SANKYO company, limited and Bristol-Myers Squibb K.K. Hideyuki Saya and Yuko Kitagawa serve as editorial board members of Cancer Science.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not involve human participants or animal subjects and was conducted entirely using\nestablished human cancer cell lines in vitro.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}